New research targets two critical enzymes involved in the production of the hormone estrogen – aromatase and steroid ...

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s (LSE: AZN) Truqap ...

Olema Pharmaceuticals palazestrant shows promise in late-stage trials for metastatic breast cancer with potential FDA ...

Hormone receptor (HR)-positive HER2-negative advanced breast cancer is incurable and the aim of treatment is to delay it getting worse and extend how long people live. If the cancer has alterations in ...

Thousands with advanced breast cancer could live long lives thanks to a new drug approved on the NHS . Capivasertib, retailed ...

Duke research saves lives; and sometimes it takes two decades.For Mei, a Duke patient with late-stage breast cancer, the ...

Use of alerts triggered by patient-reported outcome monitoring improved symptom control for patients with advanced breast cancer, according to results of the randomized PRO B trial.The approach ...

The National Institute for Health and Care Excellence (NICE) has approved the use of the tablet capivasertib, in combination ...